The placenta exchanges nutrients between the mother and the fetus and requires a constant abundant energy supply. Adiponectin (a cytokine produced primarily by adipose tissue) controls glucose and lipid homeostasis. It is well-known that maternal serum adiponectin levels are inversely related to birth weight, suggesting that adiponectin has a negative effect on fetal growth. This effect appears to be related to the control of nutrient transporters in human placenta. However, the underlying molecular mechanisms have not yet been characterized. In the present work, we studied adiponectin's direct effect on human primary cytotrophoblasts from first-trimester placenta. Our result showed that in placental cells, adiponectin 1) inhibits the expression of the major glucose transporters (GLUT1 and GLUT12) and sodium-coupled neutral amino acid transporters (SNAT1, SNAT2, and SNAT4), 2) enhances total ATP production but decreases lactate production, 3) inhibits mitochondrial biogenesis and function, and 4) stimulates cell death by enhancing the expression of the pro-apoptotic B-cell lymphoma-2 (BCL-2)-associated X protein (BAX) and tumor protein P53
INTRODUCTION
Adiponectin is a 30 kDa protein, predominantly produced by adipose tissue. In humans, it is present in high concentrations in the blood (5-15 lg/ml) [1] . This adipokine assembles as trimers (low molecular weight complexes) that may assemble further to yield hexamers (middle molecular weight forms) or more elaborate high molecular weight complexes composed of nine hexamers. In humans, the high molecular weight form is predominant in the circulation and corresponds to the active biological form of adiponectin [2] . In 2003, two specific adiponectin receptors (ADIPOR1 and ADIPOR2) were identified [3] . ADIPOR1 is ubiquitously expressed but ADIPOR2 is predominantly expressed in liver. Both receptors contain seven transmembrane domains but are structurally and functionally distinct from G-protein coupled receptors. More recently, an additional receptor for adiponectin (T-cadherin) has been described [4] . ADIPOR1 and ADIPOR2 activate a variety of signal transduction pathways such as the AMPactivated protein kinase (AMPK), protein kinase A, phosphoinositide-3 kinase, and P38/P42/P44 mitogen-activated protein kinase pathways [1, 3, 5, 6] . Adiponectin is mainly described as an insulin-sensitizing hormone with an important role in the regulation of energy metabolism [7, 8] . In skeletal muscle, for example, adiponectin stimulates glucose transport (by increasing glucose transporter [GLUT] 4 translocation [9] and activating insulin signaling) and up-regulates molecules involved in fatty acid transport, fatty acid oxidation, and energy dissipation; this results in a reduction in triglyceride content [10] . In the liver, adiponectin increases beta-oxidation [11] and decreases gluconeogenesis [12] . These metabolic effects are mainly mediated via the AMPK pathway, which acts as a key sensor of the cell's energy status. Moreover, adiponectin is known to stimulate mitochondrial biogenesis in muscle by increasing the expression of the genes encoding the peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PPARGC1A) [10, 13] , sirtuin 1 (SIRT1) [13, 14] , and nuclear respiratory factor 1 (NRF1) [14] . Furthermore, adiponectin has been shown to exert anti-inflammatory, antiangiogenic, anti-atherosclerotic, and antiproliferative roles in various cell types [15] . Lastly, various in vitro studies have reported that adiponectin promotes the apoptosis of many cell types, including human mammary and endometrial cancer cells [16] [17] [18] . Adiponectin's pro-apoptotic effects might be due, at least in part, to the direct regulation of the pro-apoptotic B-cell lymphoma-2 (BCL-2) family protein, BCL-2-associated X protein (BAX), the tumor protein P53 (TP53) gene expression, and caspase-3 activation [16, 19] .
In human pregnancy, trophoblast cells have an essential role in embryo implantation and placental development. It is now well established that trophoblast cells can differentiate according to one of two distinct pathways. In the extravillous pathway, cytotrophoblasts (CTs) proliferate, differentiate into an invasive phenotype, and penetrate into the maternal decidua and myometrium [20] . In the villous pathway, mononuclear CTs fuse to form a specialized, multinuclear syncytium called the syncytiotrophoblast (ST) on the outer layer of placental villi [20] . The ST layer performs many placental functions necessary for fetal growth and development, including nutrient and gas exchanges as well as the synthesis of steroid and peptide hormones [20] . Thus, the ST displays intense metabolic activity, and it has been estimated that it accounts for 60% of the placenta's glucose consumption. Mitochondria perform a variety of functions related to several distinct biochemical processes, such as oxidative phosphorylation, amino acid and lipid metabolism, apoptosis, and cell differentiation. The mitochondria's roles in energy production are essential for embryo development and placental function. We recently demonstrated that the mitochondrial content and expression of various nuclear factors (estrogen-related receptor gamma [ESRRG] , PPARGC1A, and SIRT1) involved in mitochondrial biogenesis and function are significantly lower in intrauterine growth restriction (IUGR) placentas than in control placentas [21] . These results suggested that mitochondrial integrity is essential for correct development of the placenta and fetal growth.
A growing body of evidence suggests that adiponectin is involved in human reproductive function and, more particularly, in the development of the fetal-placental unit [22, 23] . For example, adiponectin knockout mice are fertile [24] , but transgenic mice overexpressing adiponectin are sterile [25] . Although earlier reports suggested that adiponectin was produced by human placenta, it is now well established that this adipokine is only secreted by maternal endometrial cells [26, 27] . However, ADIPOR1 and ADIPOR2 are both expressed in human endometrium and placenta, suggesting that this adipokine has an auto/ paracrine action at the fetal-maternal interface [27, 28] . We have previously shown that adiponectin attenuates cell proliferation in human first-trimester placenta and, inversely, is able to promote both invasion and syncytialization of the human trophoblast [29, 30] . Lastly, several studies have reported that adiponectin is involved in the control of fetal growth [31] . Indeed, maternal levels of circulating adiponectin are inversely related to human fetal weight [31, 32] . Experiments performed on pregnant mice demonstrated that adiponectin injection is associated with fetal weight loss [33] . One explanation for the latter observation is that adiponectin attenuates insulin signaling and inhibits solute carries (SLC) family protein, such as the L-type amino acid transporters (LAT), sodium-coupled neutral amino acid transporters (SNAT), and GLUT3 expressions in murine placenta [28, 33] . This hypothesis was confirmed by in vitro experiments in human CTs from third-trimester placenta [34, 35] . Taken as a whole, these results suggest that adiponectin regulates fetal growth. However, the underlying molecular mechanisms have not been identified.
In view of adiponectin's known involvement in energy metabolism and fetal growth control, the objective of the present study was to specify, the adiponectin's direct effects on 1) nutrient transport and utilization, 2) mitochondrial biogenesis, and 3) cell apoptosis in human villous trophoblasts from first-trimester placenta.
MATERIALS AND METHODS

Materials
Dulbecco-modified Eagle medium and Ham F-12 nutrient mix (DMEM/ F12), penicillin, and streptomycin were purchased from Sigma Chemical Co. Fetal calf serum (FCS) was purchased from Gibco (Invitrogen). Superscript II RNase H-RT and primers were from Invitrogen, and RNAse inhibitor was obtained from AMRESCO. Nucleospin RNA II kit was obtained from Machery-Nagel. Trypsin was provided by Difco Laboratories. Recombinant human adiponectin was provided by R&D Systems Europe Ltd. The suppliers of the various antibodies used are described in the following paragraphs.
Preparation of Human Villous CTs
The study was approved by the local ethical committee (Comité Consultatif de Protection des Personnes dans la Recherche Médicale, protocol 01-78), and informed consent was provided by each donor prior to sampling. First-trimester human placental tissues (gestational age: 5-10 wk) were obtained from healthy, pregnant women aged between 22 and 44 at the time of a legal abortion. Villous CTs were prepared from the tips of placental villi as previously described [36] . The CTs were seeded in 12-well culture plates or in a LabTech culture device (1.5 3 10 6 and 6.0 3 10 4 cells per well, respectively) and cultured in phenol-red-free DMEM/F12 medium supplemented with streptomycin (10 lg/ml), penicillin (100 U/ml), and FCS (10%) at 378C under 5% CO 2 and 95% air atmosphere for 24 h. Next, CTs were cultured in DMEM/F12 medium supplemented with FCS (1%) in the presence or absence of recombinant human adiponectin (25, 250 , or 500 ng/ml) for 24 or 48 h.
Immunocytochemistry
Villous CTs were plated in a LabTech culture device (BD Biosciences) and cultured in DMEM/F12 medium supplemented with FCS (10%). After 72 h of treatment, cells were washed three times in phosphate-buffered saline (PBS) and fixed in methanol for 10 min at 48C. Nonspecific immunoglobulin G binding was prevented by incubation in PBS with 3% bovine serum albumin for 1 h at room temperature. Mouse monoclonal anti-human cytokeratin-7 primary antibody (1:100 dilution, M-7018; Dako Cytomaton) was incubated with the villous CTs for 1 h at room temperature. The slides were then rinsed with PBS and incubated with an Alexa-488-conjugated, goat-anti-mouse secondary antibody (1:400 dilution, Amax/Emax: 488/519, A-11001; Thermo Fisher Scientific Inc.) for 1 h at room temperature. Cell nuclei were counterstained with 1 lg/ml Hoechst 33258 (Sigma-Aldrich). As a negative control, villous CTs were processed in the absence of primary antibody. Immunostained samples were observed with an inverted laser scanning confocal microscope (Leica white light laser TCS SP8-X; Leica Microsystems).
Placental Explants Culture
Samples of placental tissue (gestational age: 6-10 wk) were obtained from healthy pregnant women aged between 18 and 35 at the time of a legal abortion. Placental tissues were placed in saline (150 mM NaCl), washed several times, and dissected aseptically to remove decidual tissues and fetal membranes. Placental explants were cultured on collagen type-I-coated dishes (BD Biosciences) in DMEM/F12 medium with FCS (1%) at 378C under 5% CO 2 and 95% air atmosphere for 48 h in the presence or absence of adiponectin (250 ng/ml) or the positive control staurosporin (0.1 lM).
Immunohistochemistry
Placental explants were fixed in cold phosphate-buffered neutral paraformaldehyde (4%), embedded in paraffin, and cut into 5 lm sections. For heatinduced epitope retrieval, deparaffinized sections in 0.01 M citrate buffer were treated three times for 5 min at 908C in a microwave oven. Endogenous peroxidase activity was blocked with 1% H 2 O 2 , and nonspecific immunoglobulin G binding was blocked by incubation with normal blocker serum. To study nutrient transporters expression, samples were incubated with primary GLUT1 (1:100 dilution; Millipore) and SNAT1 (1:100 dilution, sc-33441; Santa Cruz Biotechnologies, Inc.) antibodies for 1 h at room temperature. Caspase-cleaved cytokeratin-18 fragment, specific for cell apoptosis, was studied using M30 antibody (1:10 dilution, M30 CytoDEATH; Roche) for 1 h at room temperature. The slides were then rinsed and incubated with biotin-conjugated secondary antibody for 10 min at room temperature. Visualization was achieved using a 3,3 0 -diaminobenzidine (DAB) detection kit (Ventana Medical Systems). As a negative control, placental explants were processed in the absence of primary antibody. Before mounting, the slides were counterstained DUVAL ET AL.
with hematoxylin. For each culture condition, digital images of DAB-stained placenta slides were obtained at 203 magnification using a whole-slide scanner (Aperio AT2; Leica Biosystems). Specific immunostaining over three representative fields was quantified using positive pixel count algorithm from Aperio ImageScope software (http://www.leicabiosystems.com/ pathology-imaging/aperio-epathology/; Leica Biosystems).
Mitochondrial Staining
Villous CTs plated in a LabTech culture device were cultured in DMEM/ F12 medium supplemented with FCS (1%) in the presence or absence of adiponectin (25 or 250 ng/ml). After 48 h of treatment, the cells underwent mitochondrial staining with 100 nM Mitotracker Red CMXRos (Amax/ Emax: 579/599; Invitrogen) in DMEM/F12 medium supplemented with FCS (1%) for 30 min at 378C. Cells were fixed in methanol for 10 min at 48C and washed with PBS twice before cell nuclei were counterstained with Hoechst 33258 (1 lg/ml). As a negative control, villous CTs were processed in the absence of Mitotracker. Fluorescence was visualized with an inverted laser scanning confocal microscope (Leica white light laser TCS SP8-X; Leica Microsystems). Five to ten cellular events per condition were randomly selected, and Mitotracker intensity (arbitrary unit) was estimated using the postimaging procedure in ImageJ software (http://www.imagej.nih.gov/ij). Mitochondria:cell ratios were estimated by normalizing the mitochondrial staining intensity against the total number of nuclei inside each cellular event.
Quantitative Reverse Transcription Polymerase Chain Reaction
Villous CTs were seeded in a 12-well culture plate and cultured in DMEM/ F12 medium supplemented with FCS (1%) in the presence or absence of adiponectin (25, 250 , or 500 ng/ml) for 24 or 48 h. Total RNA (0.1 lg) was extracted and reverse-transcribed as previously described [37] . Quantitative PCR was performed using the C1000 Thermal Cycler (CFX96 real-time system; BioRad) and the primer sets indicated in ADIPONECTIN AND TROPHOBLAST ENERGY METABOLISM as previously described [27] . For each sample, the concentration ratios (target/ three reference mRNA) were calculated using CFX Manager (Version 3.0; BioRad) and expressed in arbitrary units. The data were expressed as percentages of the control situation. Calibration curves were log-linear over the quantification range, with correlation coefficients (r 2 ) . 0.99 and efficiencies ranging from 1.8 to 2. The intra-assay variability of duplicate crossing-point values never exceeded 0.2 cycles, and the interassay variability (coefficient of variation) ranged from 1.9% to 4.1% for 8 to 10 runs of each transcript.
Lactate Production
Lactate release in the culture medium was measured using an automated enzymatic analysis (Roche). The level was normalized to 1 lg of total proteins in the supernatant. Protein concentrations were measured according to Bradford with bovine serum albumin as the standard.
Human Chorionic Gonadotropin Secretion
The human chorionic gonadotropin (hCG) concentration was measured in the culture medium using an automated immune-chemiluminescence analysis with the total bhCG reagent kit (Abbot). In order to compare the hCG secretion, results were normalized to 1 lg of total proteins. Protein concentration was measured as described above.
ATP Production
Cellular ATP production was assessed using an ATP assay kit (ab83355; Abcam) according to the manufacturer's instructions.
RNA Interference for ADIPOR1 and ADIPOR2
Two pairs of small-interfering RNAs (siRNAs) corresponding to different regions of each receptor gene were chemically synthesized by Qiagen. The sequences of the sense siRNAs are presented in Table 2 . A fluorescently labeled, nonsilencing control siRNA (siNS) was useful for the optimization of transfection conditions and as a control for nonspecific silencing effects. For the knockdown experiments, villous CTs were plated in 12-well dishes at 1.5 3 10 6 cells per well. Cells were transfected with siRNAs (25 nM/well) using a Lipofectamine RNAiMAX transfection reagent from Invitrogen according to
-PCR (RT-qPCR) as described above.
Statistics
Statistical analysis was performed on the raw data from 6 to 10 separate experiments. A nonparametric, paired Wilcoxon test was used to compare the effect of adiponectin concentration with the control situation (i.e., the absence of adiponectin) for a given exposure time.
RESULTS
Characterization of Human Villous CTs
To assess the purity of our CT preparation, cells were cultured in DMEM/F12 medium for 72 h. We then observed two characteristics of villous CTs: the expression of cytokeratin-7 (specific for glandular epithelium) and the formation of a syncytium. Villous CTs are able to fuse spontaneously after 48À72 h of culture in vitro [38] . The microscopy analysis (Fig.  1) revealed that isolated cells presented both these characteristics; 95% of the cells stained positive for cytokeratin-7. Moreover, our cell preparation was not significantly contaminated by the other major placental cell type (extravillous CTs) because the latter require an artificial matrix for growth in vitro [39] . In parallel, we studied syncytialization of villous CTs by measuring hCG production. Our results revealed that this hormonal production gradually increased during spontaneous differentiation (1113 6 271, 4232 6 910, and 10015 6 867 mUI/lg of protein after 24, 48, and 72 h of cell culture, respectively).
Effect of Adiponectin on Nutrient Transporters
We investigated the in vitro effect of adiponectin (25, 250 , and 500 ng/ml) on GLUT1 and GLUT12 mRNA expressions (encoded by SLC2A1 and SLC2A12 genes, respectively) in villous CTs. After 24 h of treatment ( Fig. 2A) , a downregulation of GLUT1 mRNA expression by adiponectin was observed for all concentrations tested with a maximal effect at 250 ng/ml (À50%). Similarly, adiponectin decreased GLUT12 mRNA expression at 25 ng/ml and 250 ng/ml (À36% for both concentrations). After 48 h of treatment (Fig. 2B) , adiponectin significantly reduced GLUT1 mRNA expression at 250 ng/ml (À40%) with a maximal effect at 500 ng/ml (À50%). Finally, GLUT12 mRNA expression was also reduced by adiponectin at 25, 250, and 500 ng/ml (À18%, À33%, and 56%, respectively). In parallel, we studied adiponectin's effect on SNAT1, SNAT2, and SNAT4 mRNA expressions (encoded by SLC38A1, SLC38A2, and SLC38A4 genes, respectively) in villous CTs. After 24 h of treatment (Fig. 3A) , we found that adiponectin at 25 and 250 ng/ml significantly reduced SNAT1 mRNA expression (À36% and À49%, respectively). Adiponectin also reduced SNAT2 mRNA expression at 250 and 500 ng/ml (À33% and À46%, respectively). Concerning SNAT4 mRNA expression, we observed a very significant inhibition by adiponectin at only 250 ng/ml (À50%). However, in our experimental conditions, this negative effect of adiponectin on SNAT mRNA expressions did not seem to be confirmed at 48 h (Fig. 3B) .
Finally, we performed immunohistochemistry experiments in order to confirm our previous results on mRNA expressions. As shown in Figure 4 , GLUT1 and SNAT1 protein expressions are lower (À20% and À30%, respectively) in first-trimester placental cells when incubated with adiponectin (250 ng/ml) for 48 h.
Effect of Adiponectin on Energy Metabolism
To determine the effect of adiponectin on energy metabolism, we measured lactate release in cell supernatant and cellular ATP levels in the presence or absence of adiponectin (25 or 250 ng/ml). After 24 h of treatment (Fig. 5A) , lactate levels were significantly lower in presence of adiponectin at 25 and 250 ng/ml (À16% and À22%, respectively). After 48 h, we observed a significant inhibition of lactate production by adiponectin at only 250 ng/ml (À16%). In contrast, we observed a significant positive effect of adiponectin (25 and 250 ng/ml) on total (mitochondrial and cytosolic) ATP levels (þ30% and þ24%, respectively) after 48 h of exposure (Fig.  5B) .
Effect of Adiponectin on Mitochondrial Function and Biogenesis
Most of the cell's ATP is produced by the mitochondria. To assess adiponectin's effect on mitochondrial activity in villous CTs, we used a specific, fluorescent Mitotracker Red CMX Ros to stain functional mitochondria. Confocal microscopy revealed that cells incubated with adiponectin (25 or 250 ng/ ml) had significantly fewer active mitochondria than control cells (À44% and À62%, respectively) after 48 h of treatment (Fig. 6, A-E) .
In parallel, the mRNA levels of four genes involved in the mitochondrial biogenesis process (PPARGC1A, ESRRG, SIRT1, and NRF1) were studied in villous CTs exposed to adiponectin (25 or 250 ng/ml) for 24 h. Under these experimental conditions, we observed a significant decrease in PPARGC1A, ESRRG, SIRT1, and NRF1 mRNA expressions (À39%, À47%, À48%, and À47%, respectively) in human villous CTs in the presence of adiponectin at 250 ng/ml (Fig.  6F) .
Effect of Adiponectin on Cell Apoptosis
Lastly, we examined the effect of different adiponectin concentrations on the apoptotic process of villous CTs. After 24 h of treatment (Fig. 7A) , adiponectin at 25, 250, and 500 ng/ ml, significantly increased BAX mRNA expression (þ283%, þ228%, and þ513%, respectively) and TP53 mRNA expression (þ98%, þ209%, and þ524%, respectively). After 48 h of
Effect of adiponectin on glucose transporter mRNA expression in human villous CTs. CT cells were exposed to adiponectin (25, 250, or 500 ng/ ml) for 24 and 48 h. Total RNA were extracted after the treatment. GLUT1 and GLUT12 mRNA levels were quantified by RT-qPCR as described in Materials and Methods. A) Villous trophoblast cells were exposed to adiponectin for 24 h. The values are the mean 6 SEM from 13 separate experiments. B) Villous trophoblast cells were exposed to adiponectin for 48 h. The values are the mean 6 SEM from nine separate experiments.*P , 0.05; **P , 0.01; NS, nonsignificant (Wilcoxon test).
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FIG. 4. Effect of adiponectin on GLUT1 and SNAT1 protein expression in human placenta. First-trimester human placenta were exposed to adiponectin (250 ng/ml) for 48 h. GLUT1 and SNAT1 protein immunostaining were revealed as described in Materials and Methods. Magnification 320. The figure shown is representative from among seven separate experiments. A, B) GLUT1 protein immunostaining: (A) control (0 ng/ml) and (B) adiponectin (250 ng/ ml). C-E) SNAT1 protein immunostaining: (C) control (0 ng/ml), (D) adiponectin (250 ng/ml), and (E) negative control. F) Quantification of staining intensity. The area of GLUT1 and SNAT1 immunostaining was determined using Aperio ImageScope software. The values are the mean 6 SEM from seven separate experiments. *P , 0.05; **P , 0.01 (Wilcoxon test).
FIG. 3. Effect of adiponectin on amino acid transporters mRNA expression in human villous
CTs. CT cells were exposed to adiponectin (25, 250, or 500 ng/ml) for 24 and 48 h. Total RNA were extracted after treatment. SNAT1, SNAT2, and SNAT4 mRNA levels were quantified by RT-qPCR as described in Materials and Methods. A) Villous trophoblast cells were exposed to adiponectin for 24 h. The values are the mean 6 SEM from 13 separate experiments. B) Villous trophoblast cells were exposed to adiponectin for 48 h. The values are the mean 6 SEM from nine separate experiments.*P , 0.05; **P , 0.01; ***P , 0.001; NS, nonsignificant (Wilcoxon test).
DUVAL ET AL. treatment (Fig. 7B) , adiponectin up-regulated BAX mRNA expression only at 250 and 500 ng/ml (þ399% and þ1004%, respectively) but increased TP53 mRNA expression at all concentrations tested (þ48%, þ73%, and þ130%, respectively). However, in the same experimental conditions, adiponectin did not modify BCL-2 mRNA expression in human CT cells. Therefore, the BAX:BCL-2 ratio was significantly increased after 24 and 48 h adiponectin treatment.
Finally, we found that M30 immunostaining (reflecting caspase activity) was greater (þ141%) in placental explants exposed to adiponectin (250 ng/ml) for 48 h than in controls (Fig. 8, A-E) . A positive control with staurosporin (0.1 lM) gave a comparable percentage of M30 immunostaining (þ172%).
Effect of ADIPOR1 and ADIPOR2 Invalidation
In these experiments, we used two different siRNAs for each receptor. We observed a significant decrease of ADIPOR1 and ADIPOR2 mRNA expressions (À75% and À44%, respectively) after an invalidation of 48 h (Fig. 9A) . Furthermore, as shown in Figure 9B , this partial suppression of ADIPOR1 and ADIPOR2 with siRNAs abolished, significantly decreased GLUT1 mRNA expression and increased TP53 mRNA expression by adiponectin.
DISCUSSION
It is well established that birth weight is positively correlated with the mother's body mass index before and during pregnancy [40] . Moreover, the association between abnormally small or abnormally large size at birth, and obesity later in life, indicates that the risk of metabolic disease corresponds to a transgenerational transmission [41] . Fetal growth is largely dependent on the delivery of oxygen and nutrients across the placenta. The placenta's ability to supply the fetus with nutrients is determined by a multitude of factors, including the mother's nutritional status, utero-placental blood flow, and the expression and function of trophoblast nutrient transporters [42] . However, the placenta is not merely a passive conduit for nutrients; there is a growing body of evidence to suggest that the placenta acts as a nutrient sensor, integrating signals from the mother and the fetus and adapting its development as a function of the maternal nutrient environment [43] . To better understand the mechanisms governing fetalmaternal exchanges, it is important to identify the maternal and fetal factors that regulate placental function. Of the various molecules secreted at the fetal-maternal interface, adiponectin appears to have a crucial role. Several studies have shown that maternal adiponectin levels are negatively correlated with birth weight [31, 32] and consequently reduce the risk of fetal FIG. 5. Effect of adiponectin on glucose intracellular utilization in human villous CTs. CT cells were exposed to adiponectin (25 or 250 ng/ml). Lactate and ATP production were measured after 24 and 48 h as described in Materials and Methods. A) Lactate production was measured after 24 and 48 h in cell supernatants. The values are the mean 6 SEM from 10 separate experiments. The control values were 4.29 6 0.92 and 3.31 6 0.89 mmol/lg protein for 24 and 48 h, respectively. B) Total ATP production was determined after 48 h. The values are the mean 6 SEM from seven separate experiments. The control values were 0.14 6 0.03 mM ATP. *P , 0.05; **P , 0.01; NS, nonsignificant (Wilcoxon test).
ADIPONECTIN AND TROPHOBLAST ENERGY METABOLISM
FIG. 6. Effect of adiponectin on mitochondrial activity in human villous CTs.
A-E) CT cells were exposed to adiponectin (25 or 250 ng/ml) for 48 h. Mitochondrial activity was developed as described in Materials and Methods. Mitochondrial activity was analyzed by confocal microscopy. Magnification 363. The figure shown is representative from among six separate experiments. A) Control (0 ng/ml). B) Adiponectin (25 ng/ml). C) Adiponectin (250 ng/ ml). D) Negative control (absence of Mitotracker). E) Quantification of Mitotracker intensity. The area of mitochondrial staining per cell was determined using the ImageJ software available at http://imagej.nih.gov/ij. Results are the mean 6 SEM of six separate experiments. F) CT cells were exposed to adiponectin (25 or 250 ng/ml) for 24 h. Total RNA was extracted. PPARGC1A, ESRRG, SIRT1, and NRF1 mRNA levels were quantified by RT-qPCR. The values are the mean 6 SEM from eight separate experiments.*P , 0.05; **P , 0.01; NS, nonsignificant (Wilcoxon test).
FIG. 7.
Effect of adiponectin on BAX, BCL-2 and TP53 expression in human villous CTs. CT cells were exposed to adiponectin (25, 250 , or 500 ng/ml) for 24 and 48 h. Total RNA were extracted after the treatment. BAX, BCL-2, and TP53 mRNA levels were quantified by RT-qPCR as described in Materials and Methods. A) Villous trophoblast cells were exposed to adiponectin for 24 h. The values are the mean 6 SEM from 13 separate experiments. B) Villous trophoblast cells were exposed to adiponectin for 48 h. The values are the mean 6 SEM from nine separate experiments.*P , 0.05; **P , 0.01; NS, nonsignificant (Wilcoxon test).
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macrosomia [44] . However, the underlying molecular mechanisms have not been fully elucidated. In this context, we studied the in vitro effect of adiponectin on the expression of some nutrient transporters and on mitochondrial functions in human villous CTs from first-trimester placentas. In the present study, human recombinant adiponectin effects were observed with concentrations (25-500 ng/ml) much lower than those found in normal human circulation or in cord blood during gestation [45, 46] . However, the human recombinant adiponectin used in this work contains mainly the high molecular weight form [47] , known as the active form of adiponectin [48] . Moreover, adiponectin is commonly used for in vitro experiments with placental and other cell types at these subphysiological concentrations [27, 29, 30, 49] .
In contrast to the well-characterized insulin-sensitizing actions of adiponectin, our results clearly show that adiponectin FIG. 9. Role of specific adiponectin receptors on adiponectin effects in human villous CTs. CT cells were cultured for 48 h in presence of 25 nM siADIPOR1/R2 or 10 nM siNS. Total RNA were extracted after treatment and quantified by RT-qPCR as described in Materials and Methods A) ADIPOR1 and ADIPOR2 mRNA levels were measured in transfected cells. Results are the mean 6 SEM of six separate experiments. B) CT cells transfected with siADIPOR1/R2 or siNS were exposed to adiponectin (250 ng/ml). GLUT1 and TP53 mRNA levels were quantified by RT-qPCR. Results are the mean 6 SEM of eight separate experiments. *P , 0.05; **P , 0.01; NS, nonsignificant (Wilcoxon test).
ADIPONECTIN AND TROPHOBLAST ENERGY METABOLISM inhibits GLUT1 and GLUT12 expressions, the two major glucose transporter isoforms in first-trimester human villous CTs [50] . This finding agrees with Caminos et al.'s [28] report of significant down-regulation of GLUT3 mRNA expression in rat placentas after chronic adiponectin treatment during gestation. Consequently, adiponectin exerts an atypical effect on glucose homeostasis in placental tissue.
Moreover, we observed the specific down-regulation of SNAT1, SNAT2, and SNAT4 expressions, the principal amino acid transporters in placenta, in villous CTs exposed to adiponectin [51] . These data disagree with previous studies of human CTs from term placentas, which found that adiponectin exposure affects SNAT1, SNAT2, and SNAT4 expressions (only in the presence of insulin) [34, 35] . However, in vivo experiments have shown that chronic infusion of adiponectin in pregnant mice was associated with downregulation of placental amino acid transporters and a 19% drop in fetal weight [33] . Taken as a whole, these observations suggest that the effects of adiponectin on placental amino acid transport seem to be 1) gestational-age-dependent as already shown by our previous studies of the adiponectin's prodifferentiation properties [29] and 2) insulin-independent (at least in part) during the first trimester. Overall, human adiponectin seems to down-regulate placental nutrient transport during pregnancy.
Because the majority of adiponectin's metabolic effects are mediated by functional mitochondria, we next looked at this organelle's involvement in adiponectin's placental actions. First, our results demonstrate that adiponectin is associated with greater total ATP production and lower lactate production by villous CTs. Hence, adiponectin might promote aerobic glycolysis and energy production in villous CTs in order to support the placenta's high energy needs. Further experiments will be needed to complete such observations and to specify adiponectin's action on glucose metabolism in placental cells. Second, we showed that adiponectin surprisingly inhibits placental mitochondrial biogenesis by 1) reducing the expression of the main genes involved in this process (PPARGC1A, ESRRG, SIRT1, and NRF1) [52] and 2) limiting the number of functional mitochondria in villous CT cells. Our results disagree with other studies describing adiponectin as a hormone that activates mitochondrial function in organs with high metabolic activity (such as muscle and liver) [10, 13, 14] . Once again, our results describe an atypical action of adiponectin in human placenta.
Here, we found that adiponectin is associated with greater ATP production and lower concomitant mitochondrial biogenesis (i.e., fewer functional mitochondria). These paradoxical effects revealed a possible apoptotic role for adiponectin in human villous CTs. It is well-known that higher ATP production and lower mitochondrial biogenesis are observed during apoptosis [53, 54] . In this context, we studied adiponectin's effects on the apoptotic potential of villous CTs. Our results demonstrate that adiponectin up-regulates the expression of the pro-apoptotic TP53 gene and increases the BAX:BCL-2 ratio, a sign of cell apoptosis. Moreover, exposure to adiponectin was associated with more intense M30 immunostaining, suggesting that this adipokine has a proapoptotic role via caspase activity.
Moreover, silencing the ADIPOR1 and ADIPOR2 genes suppressed adiponectin effect on TP53 and also GLUT1 mRNA expressions. These results suggest a critical implication of ADIPOR in adiponectin regulation of nutrient transport and apoptosis in human villous CT cells. These results are in accordance with our previous observations describing that trophoblastic cells did not express the novel characterized adiponectin receptor, T-cadherin [27] .
Various studies have attempted to determine adiponectin's involvement in some pathologies of pregnancy and in particular IUGR, characterized by low fetal weight, small length, and small head circumference [55] . Moreover, abnormal maternal levels of adiponectin are generally observed in the context of IUGR. More precisely, maternal adiponectin concentration is lower in IUGR compared with appropriate gestational age fetuses [56] . It has also been reported that IUGR placentas present 1) abnormal mitochondrial ultrastructure, content, and function [57] and 2) marked trophoblast apoptosis and thus hypotrophic placental tissue [58, 59] . Our results showing an apoptotic effect of adiponectin in trophoblastic cells are in accordance with a previous report in which the placental adiponectin-ADIPOR1 interaction induced cell apoptosis in a context of pre-eclampsia with IUGR [60] . Adiponectin's pro-apoptotic effect has already been described in various tissues and cell types [16] [17] [18] . Placental cells consequently constitute a new example of adiponectin's decisive role in cell death. Lastly, a recent study performed in our laboratory demonstrated that the placental mitochondrial DNA content from human third-trimester placenta is directly correlated with fetal weight [21] . In the present study, we found that adiponectin modulates mitochondrial biogenesis and apoptosis in human placenta. Hence, we hypothesize that this adipokine has a causative role in the regulation of fetal growth by modulating nutrient transport and mitochondrial functions. Given the demonstrated importance of this hormone in maintaining energy homeostasis in other biological systems, there is a real need to better understand the effects of adiponectin on placental metabolism. We are currently performing experiments concerning this last point.
In conclusion, better knowledge of the underlying molecular mechanisms will enhance our understanding of how adiponectin controls placental development in normal pregnancies and also in cases of IUGR and macrosomia. In turn, this should enable mothers and children affected by these disorders to receive better care.
